Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers
NCT ID: NCT02036775
Last Updated: 2015-05-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2014-03-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers
NCT02194270
A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719
NCT01362257
Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride
NCT02572609
Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers
NCT02194283
Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics
NCT01939587
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment sequence 1
Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan prolonged-released capsules
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Treatment sequence 2
Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Treatment sequence 3
Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Treatment Sequence 4
Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Treatment sequence 5
Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Treatment Sequence 6
Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan prolonged-released capsules
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan tablet
One Lasolvan tablet 30 mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan prolonged-release hard capsule
One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Lasolvan effervescent tablet
One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female subjects aged 18-45, inclusive.
* Body mass index by Quetelet 18.50 - 24.99 kg/m2, inclusive.
* Judged by the investigator to be in good health as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, and renal systems), vital signs assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general observations. Any abnormalities outside normal ranges for any clinical testing (laboratory tests, ECG, vital signs) can be repeated at the discretion of the investigator and judged to be not clinically significant for the study participation.
* Female subjects of childbearing potential who agree on using double-barrier contraception during the study. If female is postmenopausal (no menses for at least 1 year) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) she will be exempt from the requirement. In case of using oral contraceptives, they should be withdrawn at least 2 months before the study.
* Male subjects who agree on using effective contraception during the study (barrier contraceptive methods).
Exclusion Criteria
* Known rare hereditary conditions (Stevens-Johnson syndrome, toxic epidermal necrolysis, galactose intolerance, Lapp-lactase deficiency, glucose-galactose malabsorption).
* Pregnancy or breastfeeding.
* Chronic hepatic, renal, cardiovascular, respiratory, gastrointestinal, neuroendocrine diseases and blood disorders.
* Positive results of blood tests for current infections (HIV, syphilis, hepatitis B or C).
* Surgery of gastro-intestinal tract (except of appendectomy) within the past 8 weeks.
* Acute infections occurred within 4 weeks before inclusion into the study.
* Regular drug intake within 2 weeks before inclusion into the study.
* Intake of systemic drugs known to affect cytochrome P450 system (induce or inhibit) within 4 weeks before inclusion into the study.
* Blood donation (greater or equal 450 ml) within 2 months before inclusion into the study.
* Alcohol intake greater than or equal to 10 units of alcohol per week (1 unit of alcohol equals one 50 ml single measure of whisky (ABV - alcohol by volume 40%), or 0.5 litre of beer (ABV 5%), or 200 ml glass of red wine (ABV 12%) or history of alcohol abuse, narcomania, or other drug abuse.
* A positive urine drug test (cannabis, benzodiazepines, barbiturates, opiates, cocaine, amphetamines) at screening and before the first dosing in each study period.
* A positive alcohol test at screening and before the first dosing in each study period
* Participation in another phase I clinical study within 3 months before inclusion into the study.
* Known lactose intolerance.
* Known phenylketonuria
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
18.510.2 Boehringer Ingelheim Investigational Site
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ollier C, Sent U, Mesquita M, Michel MC. Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan(R) Retard) Compared with Other Formulations in Healthy Volunteers. Pulm Ther. 2020 Jun;6(1):119-130. doi: 10.1007/s41030-020-00116-7. Epub 2020 May 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18.510
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.